10-氯7H-苯并咪唑[2,1-a]苯并[de]异喹啉-7-一 | 23982-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 10-氯7H-苯并咪唑[2,1-a]苯并[de]异喹啉-7-一
• 英文名称: 7-chloro-3,10-diazapentacyclo[10.7.1.0^2,10.0^4,9 .0^16,20]icosa-1(19),2,4(9),5,7,12,14,16(20),17-nonaen-11-on
• 英文别名: 10-chloro-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one；10-Cl-BBQ；6-Chlor-1,2-naphthoylen-benzimidazol；10-chloro-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one；10-chloro-benzo[de]benz[4,5]imidazo[2,1-a]isoquinolin-7-one；10-Chlor-benzo[de]benz[4,5]imidazo[2,1-a]isochinolin-7-on；10-chloro-7H-benzimidazo[2,1-a]benz[de]isoquinoline-7-one；7-chloro-3,10-diazapentacyclo[10.7.1.02,10.04,9.016,20]icosa-1(19),2,4(9),5,7,12,14,16(20),17-nonaen-11-one
• CAS: 23982-76-5
• 化学式: C₁₈H₉ClN₂O
• mdl: MFCD03863624
• 分子量: 304.735
• InChiKey: ZJESJVGSDQOZAT-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  10-氯7H-苯并咪唑[2,1-a]苯并[de]异喹啉-7-一 、 对甲苯磺酸甲酯 生成 Toluene-4-sulfonate10-chloro-13-methyl-7-oxo-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-13-ium;
  参考文献：
  名称：

  Campbell, Jack B.; Lavagnino, Edward R.; Paschal, Jonathan W., Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 767 - 768

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2-硝基苯胺 在 sodium hydroxide 、 溶剂黄146 、 锌 作用下， 生成 10-氯7H-苯并咪唑[2,1-a]苯并[de]异喹啉-7-一
  参考文献：
  名称：

  Okazaki et al., Yuki Gosei Kagaku Kyokaishi, 1955, vol. 13, p. 413,415

  摘要：

  DOI：

文献信息

• [EN] ARYL HYDROCARBON RECEPTOR ACTIVATORS<br/>[FR] ACTIVATEURS DU RÉCEPTEUR D'HYDROCARBURE ARYLE
  申请人：UNIV OREGON STATE

  公开号：WO2021022061A1

  公开（公告）日：2021-02-04

  Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.

  披露了小分子AhR配体。这些配体可以诱导Tr1细胞分化，抑制病原免疫反应，而不引起非特异性免疫抑制。还披露了使用AhR配体治疗自身免疫疾病的方法。
• Compounds and methods to suppress autoimmune response
  申请人：Oregon State University

  公开号：US10308649B2

  公开（公告）日：2019-06-04

  A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (AhR) ligand. The AhR ligand includes 11-Cl-BBQ, 10-Cl-BBQ, an analog of 11-Cl-BBQ, or combination thereof. The AhR ligand is administered topically, orally, transdermally, intravenously, subcutaneously, or with a nanoparticle. The AhR ligand induces regulatory T cells (AhR-Tregs). AhR-Treg cells block the differentiation of cytotoxic T-lymphocytes (CTL). The AhR ligand activates AhR in CD4+ T cells to induce CD4+ AhR-Tregs that suppress the development of effector CTL, thereby suppressing the development of CTL that attack host cells in graft versus host disease (GVHD) or β-cells in the pancreas in diabetes mellitus type 1 (T1DM). The AhR ligand can also suppress development of CTL independently of Foxp3+ regulatory T cell induction. The AhR ligand can therefore be used to treat autoimmune diseases characterized by an absence of functional Foxp3+ regulatory T cell.

  一种治疗自身免疫性疾病的组合物和方法包括施用有效量的芳基烃受体（AhR）配体。AhR 配体包括 11-Cl-BBQ、10-Cl-BBQ、11-Cl-BBQ 的类似物或其组合。AhR 配体可局部给药、口服、透皮给药、静脉注射、皮下注射或用纳米颗粒给药。AhR 配体可诱导调节性 T 细胞（AhR-Tregs）。AhR-Treg细胞可阻止细胞毒性T淋巴细胞（CTL）的分化。AhR 配体激活 CD4+ T 细胞中的 AhR，诱导 CD4+ AhR-Tregs，抑制效应 CTL 的发育，从而抑制 CTL 的发育，CTL 会攻击移植物抗宿主疾病（GVHD）中的宿主细胞或 1 型糖尿病（T1DM）胰腺中的β细胞。AhR 配体还能抑制 CTL 的发展，而不依赖于 Foxp3+ 调节性 T 细胞的诱导。因此，AhR 配体可用于治疗以缺乏功能性 Foxp3+ 调节性 T 细胞为特征的自身免疫性疾病。
• COMPOUNDS TO SUPPRESS AUTOIMMUNE RESPONSE
  申请人：OREGON STATE UNIVERSITY

  公开号：EP3212634B1

  公开（公告）日：2021-04-21
• COMPOUNDS AND METHODS TO SUPPRESS AUTOIMMUNE RESPONSE
  申请人：Oregon State University

  公开号：US20180030048A1

  公开（公告）日：2018-02-01

  A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (AhR) ligand. The AhR ligand includes 11-Cl-BBQ, 10-Cl-BBQ, an analog of 11-Cl-BBQ, or combination thereof. The AhR ligand is administered topically, orally, transdermally, intravenously, subcutaneously, or with a nanoparticle. The AhR ligand induces regulatory T cells (AhR-Tregs). AhR-Treg cells block the differentiation of cytotoxic T-lymphocytes (CTL). The AhR ligand activates AhR in CD4+ T cells to induce CD4+ AhR-Tregs that suppress the development of effector CTL, thereby suppressing the development of CTL that attack host cells in graft versus host disease (GVHD) or β-cells in the pancreas in diabetes mellitus type 1 (T1DM). The AhR ligand can also suppress development of CTL independently of Foxp3+ regulatory T cell induction. The AhR ligand can therefore be used to treat autoimmune diseases characterized by an absence of functional Foxp3+ regulatory T cell.
• US4413126A
  申请人：——

  公开号：US4413126A

  公开（公告）日：1983-11-01